We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bermuda ...
"And yet" ............... we are still in trial .. ATB
Inanaco,
Well I did clearly state IMO.
You're correct, we don't know the efficacy of Modi1 yet - but we have excellent results from SCIB1 in small patient numbers and yet...…………..……………………….
Michaelhighbar
I don't think it would help at this stage, you can actually compare the trial with that genexine GX188 trial with Merck not huge patient numbers .. so i am happy that its done inhouse, better to sell the data ...than the principle behind the synergy
Cars its not the same as TCR ..
Ray
Also, are the actions of the TILs suppressed by TRegs meaning that the addition of a CI may be helpful?
only trial results would allow discussions of how its used and with what ..
I would be careful about making definitive statements like that Bermuda ... just simply because we do not know the Efficacy level yet .
Sounds pricey compared to a little jab ! Is it in principle the same as TCR ?
Just had my top up at 5.95 , looking forward to next week .
Have a good weekend all .
https://achillestx.com/science/
It's an interesting science.
1) TILs are removed from a patient's tumour
2) Dendritic cells are removed from the patient's blood
3) The targets are identified on a patient by patient basis
4) The peptides are created for the patient's targets
5) The peptides are added to the dendritic cells
6) The peptides are presented to the TILs to perform activation
7) The activated TILs are expanded in number
8) The activated TILs are re-infused into the patient
I can't find any mention of avidity on the website.
Also, are the actions of the TILs suppressed by TRegs meaning that the addition of a CI may be helpful?
Inanaco, let's be realistic DID any Pharma want to buy or Partner SCIB1. It seems that It was successful. You can give all the explanations you want with your knowledge of the science . I'm honest enough to say I know little about the science. In what way will the results of Achilles trial affect SCIB1. Whether It's a good or bad result It will mean nothing to Sclp. Scancell have a good Drug but no body up to today wants It. Read Michaelhighbar's post I would IMO say that's a fairly general opinion on Sclp position at present. Can respect your positive commitment. None of us win unless there Is positives. IMO.
Michaelhighbar,
I completely agree. IMO Scancell simply don't have the infrastructure or the ability to raise sufficient funds to take any of the pipeline beyond a phase I/IIa trial and the investment case here is either a licensing deal or sale. Time will tell!
Bermuda, thanks for the link. Good to see yet one more confirmation that it's not only Covid trials that are currently going on.
Fully share your sentiment re getting on with SCIB and an update on Moditope. It's taken years for Scancell to get the regulatory approvals for Phase II SCIB1 and, ultimately, praise should be given where due. Whether such delays were difficult to avoid or be mitigated, is a matter for a debate. Looking forward, let's hope that the cancer trials won't be delayed any further.
Or, after almost 10 years, having got the principles of the science behind SCIB1 established coupled with some early successes, maybe it's a very good time for a licensee or a joint-venture partner to come in? It may well be that the progress of SCIB1 would be accelerated if a party with more experience with clinical trials, that can tap into more resources and with ... stronger project management skills was to come in either alongside Scancell or even to take over the process.
Its a personal treatment .... completely different to Scancells
a previous posts of yours gave the impression that you did not understand the science behind SCIB1 and indeed the effect of Keytruda ..
i suggest you wait until this current trial by Achillies Therapeutics is over, then the follow up trial will probably be with a check point like keytruda
its all baby steps unless of course your treating a pandemic
Berm, Would you wonder why Achilles are going ahead with that treatment, after seeing that Scancell got little Interest for SCIB1 after having such good results. Could they not try and do a deal with Scancell for SCIB1. Surely wouldn't be hard to deal with Scancell after SCIB1 sitting there for 4 years. Am I being too simplistic. IMO.
that really is good new ... thanks
Achillies Therapeutics announced this morning that they have dosed the first patient in their melanoma clinical trial which is recruiting in both Manchester and Newcastle. This is a really positive sign and shows that cancer trials in the UK are getting going again.
Very much hope that Scancell can quickly get back to their core business and put everything they have into getting recruitment started in the UK for SCIB1 and study centres agreed for the US. Would also be great to have an update on Moditope, in particular where they are with manufacture and the impact of COVID-19 on timescales.
https://achillestx.com/achilles-therapeutics-doses-first-patient-in-phase-i-ii-study-in-recurrent-or-metastatic-malignant-melanoma-with-first-til-therapy-to-specifically-target-clonal-neoantigens/